October 10, 2023

Crinetics Announces October 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new non-executive employees

September 20, 2023

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

Crinetics management will participate in a fireside chat and conduct investor meetings at the Cantor Global Healthcare Conference on September 26, 2023

September 12, 2023

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894 and its other research and development programs, and for working capital and general corporate purposes.

September 11, 2023

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Crinetics announced today that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering.

September 10, 2023

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

Crinetics Pharmaceuticals reports that paltusotine, an oral, once-daily investigational compound, met the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1 study